Safety, acceptability and adhesion of a novel bioadhesive, slow-release tablet of miconazole in a phase I study

Journal de Mycologie Medicale

Volumn 13, Issue 1, 2003, Pages 13-18

  Chaumont, C ^a   Cardot, J M ^b   Dubray, C ^c   Constantini, D ^a   Aiache, J M ^b  

^a BioAlliance Pharma   (France)

^b Lab Microbiologie Lab P   (France)

^c UNIVERSITÉ CLERMONT AUVERGNE   (France)

Author keywords

Antifungal; Bioadhesive tablet; Drug delivery system; Miconazole; Milk protein; Phase I study

Indexed keywords

MICONAZOLE;

ABDOMINAL PAIN; ADULT; ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDIASIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GEL; HEADACHE; HUMAN; MALE; MOUTH CAVITY; MUCOSA INFLAMMATION; PATIENT COMPLIANCE; PHASE 1 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SLOW RELEASE FORMULATION;

FUNGI;

EID: 0037356695     PISSN: 11565233     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Bouckaert S, Schautteet H, Lefebvre RA, Remon JP, van Clooster R. Comparison of salivary miconazole concentrations after administration of a bioadhesive slow-release buccal tablet and an oral gel. Eur J Clin Pharmacol 1992;43:137-40
2. Brincker H. Treatment of oral candidiasis in debilitated patients with miconazole - a new potent antifungal drug. Scand J Infect Dis 1976;8:117-20.
3. Brugmans J, van Custem J, Heykants J, Schuermans V, Thienpont D. Systemic antifungal potential, safety, biotransport and transformation of miconazole nitrate. Eur J Clin Pharmacol 1972;5:93-9.
4. Dias AP, Samaranayake LP, Lee MT. Miconazole lacquer in the treatment of denture stomatitis: clinical and microbiological findings in Chinese patients. Clin Oral Investig 1997;1:47-52.
5. Ellepola AN, Samaranayake LP. Antimycotic agents in oral candidosis: an overview: 2. Treatment of oral candidosis. Dent Update 2000;27:165-70.
6. Epstein JB, Stevenson-Moore P. Periodontal disease and periodontal management in patients with cancer. Oral Oncol 2001;37:613-9.
7. Hoesley C, Dismukes WE. Overview of oral azole drugs as systemic anti-fungal therapy. Semin Resp Crit Care Med 1997;18:301-9.
8. Lesse AJ. Antifungal agents. In: Essentials of Pharmacology. Saunder, Edited by CM Smith, A Reynard. Philadelphia, pp. 404-11.
9. Meis JF, Verweij PE. Current management of fungal infections. Drugs 2001;61:13-25.
10. Parvinen T, Kokko J, Yli-Urpo A. Miconazole lacquer compared with gel in treatment of denture stomatitis. Scand J Dent Res 1994;102:361-6.
11. Powderly WG, Gallant JE, Ghannoum MA, Mayer KH, Navarro EE, Perfect JR. Oropharyngeal candidiasis in patients with HIV: suggested guidelines for therapy. AIDS research and human retroviruses 1999;15:1619-23.
12. Reading JH, Clifford PD, Coles RW, Rajagopalan N. An open assessment of miconazole oral gel in the treatment of paediatric oral candidosis in general practice. Curr Ther Res 1981;30:605-10.
13. Rex JH, Walsh TJ, Sobel JD, Filler SG, Pappas PG, Dismukes WE, et al. Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America. Clin Infect Dis 2000;30:662-78.
14. Rindum JL, Holmstrup P, Pedersen M, Rassing MR, Stoltze K. Miconazole chewing gum for treatment of chronic oral candidosis. Scand J Dent Res 1993;101:386-90.
15. Roed-Petersen B. Miconazole in the treatment of oral candidosis. Int J Oral Surg 1978;7:558-63.
16. Samaranayake LP, Holmstrup P. Oral candidiasis and human immunodeficiency virus infection. J Oral Pathol Med 1989;18:554-64.
17. Vazquez JA. Options for the management of mucosal candidiasis in patients with AIDS and HIV infection. Pharmacotherapy 1999;19:76-87.
18. Weinert M, Grimes RM, Lynch DP. Oral manifestations of HIV infection. Ann Intern Med 1996;125:485-96.